| Literature DB >> 24770373 |
Daniel Medenwald1, Jan A Kors2, Harald Loppnow3, Joachim Thiery4, Alexander Kluttig1, Sebastian Nuding2, Daniel Tiller1, Karin H Greiser5, Karl Werdan2, Johannes Haerting1.
Abstract
BACKGROUND: Previous research found an association of CRP with QT time in population based samples. Even more, there is evidence of a substantial involvement of the tumor necrosis factor-alpha system in the pathophysiology of cardiac arrhythmia, while the role of Interleukin 6 remains inconclusive.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24770373 PMCID: PMC4000193 DOI: 10.1371/journal.pone.0095994
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the CARLA collective – differentiated according to sex and presence of prolonged QT time.
| Men QTc < 450 ms | Men QTc > 450 ms | p† | Women QTc < 460 ms | Women QTc > 460 ms | p† | |
| [95% CI] | [95% CI] | [95% CI] | [95% CI] | |||
| N | 796 (46,4%) | 123 (7,2%) | - | 722 (42.1%) | 75 (4,4%) | - |
| cQT [ms] | 417.79 [416.52, 419.07] | 468.8 [465.85, 471.78] | - | 423.11 [421.77, 424.46] | 476.48 [473.03, 479.95] | - |
| sTNF-R1 [pg/mL] | 1159.85 [1129.41, 1191.11] | 1230.39 [1133.3, 1335.79] | 0.1243 | 1047.56 [1019.81, 1076.05] | 1266.6 [1148.62, 1396.69] | <.0001 |
| IL-6 [pg/mL] | 1.68 [1.55, 1.81] | 2.26 [1.9, 2.69] | 0.0045 | 1.83 [1.69, 1.97] | 2.56 [1.95, 3.36] | 0.0106 |
| hsCRP [mg/L] | 2.02 [1.86, 2.2] | 2.61 [2.21, 3.08] | 0.0251 | 1.85 [1.69, 2.02] | 2.38 [1.86, 3.04] | 0.0757 |
| BMI [kg/m2] | 27.65 [27.38, 27.92] | 28.89 [28.13, 29.66] | 0.0014 | 27.94 [27.57, 28.31] | 29.73 [28.63, 30.88] | 0.0047 |
| Age [years] | 62.87 [62.18, 63.58] | 68.36 [66.66, 70.09] | <.0001 | 62.33 [61.63, 63.04] | 66.88 [64.75, 69.09] | 0.0002 |
| Syst. BP [mmHg] | 143.97 [142.65, 145.3] | 150.13 [146.32, 154.05] | 0.0013 | 139.79 [138.19, 141.4] | 142.87 [138.53, 147.35] | 0.2488 |
| Glucose [mmol/l] | 5.87 [5.78, 5.97] | 6.33 [6.02, 6.67] | 0.0008 | 5.62 [5.53, 5.7] | 5.99 [5.66, 6.35] | 0.0102 |
| Cholesterol [mg/day] | 5.29 [5.22, 5.36] | 5.23 [5.05, 5.41] | 0.531 | 5.63 [5.55, 5.71] | 5.67 [5.4, 5.95] | 0.7379 |
| HDL [mmol/l] | 1.23 [1.21, 1.25] | 1.2 [1.15, 1.26] | 0.3997 | 1.51 [1.48, 1.54] | 1.51 [1.42, 1.61] | 0.9586 |
| Triglycerides[mmol/l] | 1.77 [1.71, 1.85] | 1.89 [1.72, 2.08] | 0.2519 | 1.42 [1.37, 1.48] | 1.48 [1.32, 1.66] | 0.5051 |
| TSH [mmol/l] | 0.75 [0.71, 0.8] | 0.82 [0.73, 0.92] | 0.2876 | 0.75 [0.7, 0.81] | 0.65 [0.49, 0.85] | 0.1848 |
| Alcohol [g/day] | 1.48 [1.07, 2.05] | 1.06 [0.44, 2.54] | 0.4521 | 0.02 [0.01, 0.03] | 0.04 [0.01, 0.12] | 0.3864 |
|
| ||||||
| Antiarrhythmic medication** | 5 (0,6%) | 1 (0,5%) | 0.2187 | 4 (0,5%) | 1 (1,3%) | 0.3750 |
| Antiphlogistic medication** | 4 (0,5%) | 1 (0,5) | 0.3750 | 7 (1%) | 1 (1,3%) | 0.0703 |
| QT prolonging medication ** | 89 (11.2%) | 25 (20.3%) | 0.0042 | 82 (11.4%) | 10 (13.3) | 0.6103 |
Geometric means with respective 95% confidence intervals.
Abbreviation: cQT: Bazett corrected QT interval; sTNF-R1: Soluble tumor necrosis factor type 1; hsCRP: High-sensitive C-reactive protein; IL-6: Interleukin 6; BMI: Body mass index; BP = Blood pressure; HDL: High density lipoprotein; TSH: Thyroid stimulating hormone.
* Proportion referred to the whole sample, ** Proportion within subgroup; †p-values refer to subgroups differences of subject with and without prolonged QT time within sexes.
Figure 1Association of prolonged QTc time and inflammation parameters.
Odds ratios (OR) with 95% confidence interval. Unadjusted regression models of inflammation parameter. OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
Figure 2Association of prolonged QTc time and inflammation parameters.
Odds ratios (OR) with 95% confidence interval. Models were adjusted for age, anti-arrhythmic (ATC code: C01B) and anti-phlogistic medication (ATC code: A07), current smoking status, high density lipoprotein (HDL), cholesterol, glucose blood level, alcohol intake, body mass index, thyroid stimulating hormone (TSH), systolic blood pressure and potentially QT prolonging drugs (see www.qtdrugs.org). OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
Linear regression of QTc, QT time and heart rate (HR) on sTNF-R1 in men and women (estimates with 95% confidence interval).
| QTc [ms] | Men | Women | Men**[95% CI] | Women**[95% CI] |
| sTNF-R1 [1000 pg/mL] | 5.41 [2.52, 8.30] | 8.46 [4.81, 12.11] | −0.22 [−3.44, 3] | 5.75 [1.32, 10.18] |
| hsCRP [10 mg/L] | 6.8 [2.68, 10.92] | 2.94 [0.71, 5.18] | 2.17 [−1.96, 6.3] | 2.02 [−0.23, 4.27] |
| IL-6 [10 pg/mL] | −0.11 [−0.93, 0.7] | −0.54 [−0.96, −0.12] | −0.2 [−0.98, 0.59] | −0.51 [−0.93, −0.09] |
Estimates refer to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
*unadjusted values; ** covariate adjusted values: models were adjusted age, anti-arrhythmic (ATC code: C01B) and anti-phlogistic medication (ATC code: A07), current smoking status, high density lipoprotein (HDL), cholesterol, glucose blood level, alcohol intake, body mass index, thyroid stimulating hormone (TSH), systolic blood pressure and potentially QT prolonging drugs (see www.qtdrugs.org).
OR refers to a 1,000 pg/mL increase in sTNF-R1, a 10 pg/mL increase in IL-6, and a 10 mg/L increase in hsCRP.
Figure 3Scatter plot of corrected QT time dependent on sTNF-R1.
x-axis: Soluble tumor necrosis factor type 1 (sTNF-R1) in pg/mL; y-axis: heart rate corrected QT time (QTc) in ms.